ALBUQUERQUE, N.M., Oct. 31 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology, announced today it hired Manzano Strategies LLC, a government consulting firm focused on building government partnerships with companies interested in defense appropriations and development of advanced technologies.
Manzano Strategies' (http://www.manzanostrategies.com) partners David Montoya and Bruce Donisthorpe will spearhead efforts with the New Mexico legislature and federal government in promoting programs using Biomoda's early lung cancer detection technology based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope.
Before launching Manzano Strategies, Montoya served as Chief of Staff of Los Alamos National Laboratory's Nuclear Weapons Program. He served as a senior policy advisor to Senator Jeff Bingaman, responsible for defense, veterans' affairs, economic development and other programs. Donisthorpe was Legislative Director for Representative Joe Skeen and an Associate Staff Member of the US House Appropriations Committee prior to entering private business as a government affairs advisor for New Mexico Institute of Mining and Technology (New Mexico Tech), among other high-technology and defense- related clients.
"David and Bruce represent two of the best advisors in the country related to our work with the government in securing support for programs that will help our veterans and the military in the field of health care," said John Cousins, President of Biomoda. "We look forward to using every bit of their expertise in promoting Biomoda on a national scale."
Biomoda's, the patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.
Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.
Contact: John Cousins (505) 821-0875
|SOURCE Biomoda, Inc.|
Copyright©2007 PR Newswire.
All rights reserved